The Duration of Pharyngeal Gonorrhea: A Natural History Study.


Journal

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213

Informations de publication

Date de publication:
16 08 2021
Historique:
received: 30 09 2020
pubmed: 30 1 2021
medline: 23 9 2021
entrez: 29 1 2021
Statut: ppublish

Résumé

Pharyngeal gonorrhea is relatively common. However, the duration of untreated pharyngeal gonorrhea is unknown. From March 2016 to December 2018, we enrolled 140 men who have sex with men in a 48-week cohort study. Participants self-collected pharyngeal specimens and completed a survey weekly. Specimens were tested using a nucleic acid amplification test at the conclusion of the study. We estimated the incidence and duration of infection. We defined incident infections as 2 consecutive positive tests, and clearance as 2 consecutive negative tests; and, after visual inspection of the data, we reclassified up to 2 weeks of missing or negative tests as positive if they occurred between 2 episodes of infections. We used Kaplan-Meier estimates to define duration of infection. Finally, we report on the frequency of single-positive tests and the time between the last negative test and the positive test. Nineteen (13.6%) of 140 participants experienced 21 pharyngeal infections (incidence, 31.7/100 person-years; 95% confidence interval, 20.7-48.6/100 person-years). The estimated median duration of pharyngeal gonorrhea was 16.3 weeks (95% confidence interval, 5.1-19.7 weeks). Twenty-two men had 25 single-positive specimens, a median of 7 days (interquartile range, 7-10 days) after their last negative test. The median duration of untreated pharyngeal gonorrhea is 16 weeks, more than double previous estimates. This long duration of infection likely contributes to high levels of gonorrhea transmission.

Sections du résumé

BACKGROUND
Pharyngeal gonorrhea is relatively common. However, the duration of untreated pharyngeal gonorrhea is unknown.
METHODS
From March 2016 to December 2018, we enrolled 140 men who have sex with men in a 48-week cohort study. Participants self-collected pharyngeal specimens and completed a survey weekly. Specimens were tested using a nucleic acid amplification test at the conclusion of the study. We estimated the incidence and duration of infection. We defined incident infections as 2 consecutive positive tests, and clearance as 2 consecutive negative tests; and, after visual inspection of the data, we reclassified up to 2 weeks of missing or negative tests as positive if they occurred between 2 episodes of infections. We used Kaplan-Meier estimates to define duration of infection. Finally, we report on the frequency of single-positive tests and the time between the last negative test and the positive test.
RESULTS
Nineteen (13.6%) of 140 participants experienced 21 pharyngeal infections (incidence, 31.7/100 person-years; 95% confidence interval, 20.7-48.6/100 person-years). The estimated median duration of pharyngeal gonorrhea was 16.3 weeks (95% confidence interval, 5.1-19.7 weeks). Twenty-two men had 25 single-positive specimens, a median of 7 days (interquartile range, 7-10 days) after their last negative test.
CONCLUSIONS
The median duration of untreated pharyngeal gonorrhea is 16 weeks, more than double previous estimates. This long duration of infection likely contributes to high levels of gonorrhea transmission.

Identifiants

pubmed: 33513222
pii: 6123922
doi: 10.1093/cid/ciab071
pmc: PMC8366826
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

575-582

Subventions

Organisme : NIAID NIH HHS
ID : K23 AI113185
Pays : United States
Organisme : NIAID NIH HHS
ID : P30 AI027757
Pays : United States
Organisme : Hologic
Organisme : NCATS NIH HHS
Pays : United States
Organisme : NIH HHS
ID : UL1 TR002319
Pays : United States
Organisme : National Institute of Allergy and Infectious Diseases
Organisme : NCI NIH HHS
Pays : United States
Organisme : NIMH NIH HHS
Pays : United States
Organisme : NIDA NIH HHS
Pays : United States
Organisme : Eunice Kennedy Shriver National Institute of Child Health and Human Development
Organisme : NHLBI NIH HHS
Pays : United States
Organisme : NIA NIH HHS
Pays : United States
Organisme : NIGMS NIH HHS
Pays : United States
Organisme : NIDDK NIH HHS
Pays : United States

Commentaires et corrections

Type : CommentIn

Informations de copyright

© The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Auteurs

Lindley A Barbee (LA)

Division of Infectious Diseases, Department of Medicine, University of Washington, Seattle, Washington, USA.
Public Health-Seattle & King County HIV/STD Program, Seattle, Washington, USA.

Olusegun O Soge (OO)

Neisseria Reference Laboratory, Department of Global Health, University of Washington, Seattle, Washington, USA.

Christine M Khosropour (CM)

Department of Epidemiology, University of Washington, Seattle, Washington, USA.

Micaela Haglund (M)

Division of Infectious Diseases, Department of Medicine, University of Washington, Seattle, Washington, USA.

Winnie Yeung (W)

Division of Infectious Diseases, Department of Medicine, University of Washington, Seattle, Washington, USA.

James Hughes (J)

Department of Biostatistics, University of Washington, Seattle, Washington, USA.

Matthew R Golden (MR)

Division of Infectious Diseases, Department of Medicine, University of Washington, Seattle, Washington, USA.
Public Health-Seattle & King County HIV/STD Program, Seattle, Washington, USA.
Department of Epidemiology, University of Washington, Seattle, Washington, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH